An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC

Author(s):
Koopman, L.A.; Janmaat, M.L.; Jacobsen, K.; Terp, M.G.; Gresnigt-van den Heuvel, E.; Forssman, U.; Lingnau, A.; Parren, P.W.; Ditzel, H.; Breij, E.C.
Published
2018
Publication type
Other
Date issued
2018-07-01
Language
English
Publisher
AMER ASSOC CANCER RESEARCH
hdl
1887/121517
doi
10.1158/1538-7445.AM2018-832